title: Immunotoxicological investigation using pharmaceutical drugs. In vitro evaluation of immune effects using rodent or human immune cells.
abstract: In order to evaluate the relevance of in vitro methods for immunotoxicity assessment, the effects of pharmaceutical drugs on lymphoproliferative and cytotoxic functions of mouse splenocytes and human peripheral blood mononuclear cells (hPBMC) were studied. A comparison of sensitivity of immune cells from different origins to an in vitro exposure to different xenobiotics was performed using non-immunosuppressive (cimetidine and furosemide) and immunosuppressive (azathioprine (AZA), cyclosporine A (CSA), and dexamethasone (DEX)) drugs. For CSA, sensitivity of both rat and mouse splenocytes following in vitro exposure was compared to the one of hPBMC. Immune function tests included lymphoproliferative response to mitogenic lectins (concanavalin A (Con A) and phytohemagglutinin (PHA-P)) or to allogeneic cells (mixed leukocyte response (MLR)) and cytotoxicity assays (cytotoxic-T lymphocyte (CTL) and natural killer (NK) cell-mediated cytolysis). Additionally, to evaluate how well in vitro assays represent the in vivo situation, a comparison of the effect of cyclosporine A on the same immune function tests following in vivo or in vitro exposure was performed. The data obtained show numerous similarities in the effects observed following in vitro exposure of rodent or human cells to the drugs and a very similar sensitivity of rat and mouse cells to CSA in vitro. Discrepancies between human and rodent cells such as lymphoproliferative response to PHA-P following exposure to DEX or sensitivity of CTL-mediated cytolysis to CSA do exist. In vitro assays were very representative of the in vivo situation, both in the rat and in the mouse, following CSA exposure, except for NK cell activity in the rat. These data show the usefulness of in vitro systems for immunotoxicity assessment. They allow direct comparison of rodent and human systems, and could be representative, for drugs altering specifically the immune system like CSA does, of the in vivo situation.
authors.affiliation: Laboratoire de Toxicologie, INSERM CJF 93-01, Faculté de Pharmacie Paris XI, Chatenay-Malabry, France.
authors.forename: H
authors.initials: H
authors.lastname: Lebrec
authors.forename: R
authors.initials: R
authors.lastname: Roger
authors.forename: C
authors.initials: C
authors.lastname: Blot
authors.forename: G R
authors.initials: GR
authors.lastname: Burleson
authors.forename: C
authors.initials: C
authors.lastname: Bohuon
authors.forename: M
authors.initials: M
authors.lastname: Pallardy
mesh_terms: D000818:Animals; D002470:Cell Survival / Q000187:drug effects; D002927:Cimetidine / Q000633:toxicity; D016572:Cyclosporine / Q000633:toxicity; D005665:Furosemide / Q000633:toxicity; D006801:Humans; D007166:Immunosuppressive Agents / Q000633:toxicity*; D066298:In Vitro Techniques; D007694:Killer Cells, Natural / Q000187:drug effects; D007963:Leukocytes, Mononuclear / Q000187:drug effects*; D008214:Lymphocytes / Q000187:drug effects*; D051379:Mice; D051381:Rats; D013047:Specific Pathogen-Free Organisms; D013154:Spleen / Q000166:cytology / Q000187:drug effects; D013602:T-Lymphocytes, Cytotoxic / Q000187:drug effects
chemical_list: D007166:Immunosuppressive Agents; D005665:Furosemide; D002927:Cimetidine; D016572:Cyclosporine